Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Indometacin suppository
The First People's Hospital of Lianyungang
Pancreatitis, Chronic
1 trial -
Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
The First People's Hospital of Lianyungang
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
Hospital Authority, Hong Kong
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-Pro regimen
The First People's Hospital of Lianyungang
Diffuse Large B-Cell Lymphoma
1 trial -
Infant and young child feeding
United Therapeutics Europe Ltd
Growth; Stunting, Nutritional
1 trial -
Infasurf
Summit Therapeutics
Respiratory Distress Syndrome
1 trial -
Influence of propofol sedation on memory consolidation and 'working memory'
The First People's Hospital of Lianyungang
Memory Impairment
1 trial -
Infrared thermography
The First People's Hospital of Lianyungang
Chronic Obstructive Pulmonary Disease
1 trial -
Insulin
The First People's Hospital of Lianyungang
Gestational Diabetes
1 trial -
Insulin
United Therapeutics Europe Ltd
Burns
1 trial -
Insulin Aspart Injection(UBLIN®)
United Therapeutics Europe Ltd
Pharmacokinetics and Pharmacodynamics
1 trial -
Intensity-modulated radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Interleukin-2
The First People's Hospital of Lianyungang
Beta Thalassemia Major
1 trial -
Intraoperative Radiation Therapy in Malignant Cerebral Tumor
The First People's Hospital of Lianyungang
Glioblastoma
1 trial -
Intrathecal recombinant human alpha iduronidase
Ultragenyx UK Limited
Mucopolysaccharidosis I
1 trial -
Intrauterine lavage therapy
The First People's Hospital of Lianyungang
Intrauterine Adhesions
1 trial -
Intravenous Anesthetic Induction with Ciprofol for Painless Colonoscopy in Elderly Patients
The First People's Hospital of Lianyungang
Ciprofol
1 trial -
Intravenous Vitamin C
United Therapeutics Europe Ltd
Burns
1 trial -
Intravenous administration of ferric carboxymaltose
United Therapeutics Europe Ltd
Lung Hypoxia
1 trial -
Intravenous sedation
United Therapeutics Europe Ltd
Lower Back Pain
1 trial -
Intravenous tramadol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Catheter Site Discomfort
1 trial -
Ipilimumab
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial -
Irinotecan Hydrochloride Liposome Injection;Carboplatin Injection;Serplulimab Injection
The First People's Hospital of Lianyungang
Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources